M&AHealthcarePUBLISHED
Lilly Invests €156 Million to Expand Spanish Obesity Drug Production
Value
€156M
Acquirer
Lilly
Target
Alcobendas plant
Pharma giant Lilly is investing €156 million to increase production capacity at its Alcobendas plant in Spain for its oral obesity therapy, Orforglipron. The drug is slated for export to 120 countries, with EU approval anticipated this year or in 2027.
The Meridian Weekly
The week's largest deals and the Iberian ones, every Monday. Free.